( BLUD) were among the best-performing health-related stocks Thursday, rising 7% after the company posted better-than-expected third-quarter results.
The company, which sells reagents and systems used to identify the properties of blood prior to a transfusion, earned $11.7 million, or 25 cents a share, on revenue of $47.1 million. Analysts polled by Thomson First Call expected earnings of 23 cents a share and revenue of $47 million. During the year-earlier period, Immucor earned $6.5 million, or 14 cents a share, on revenue of $38 million. The company attributed the year-over-year sales jump to price increases.
Nasdaq Powers Past Record High Amid Bond Market Lull; Tesla Extends Gains
With investors content to buy into Fed Chairman Jerome Powell's inflation optimism, bond markets are holding steady and stocks are looking to test fresh record highs.
Immucor sees fiscal 2006 earnings of $38.3 million to $40.6 million, or 81 cents to 85 cents a share. The company predicts revenue of $180 million to $183 million, while gross margin is expected to range from 65% to 66%. Analysts project earnings of 84 cents a share and revenue of $182.1 million. Immucor shares recently were up $2.14 to $30.90.
shares jumped 30% after the Food and Drug Administration approved the company's new CoolWave control unit, which is used in the treatment of benign prostatic hyperplasia. The medical-device maker plans to launch the product between July and September. "The new user interface and increased processing power of CoolWave allow our urologists to set customized treatments for their BPH patients, including those with small glands and symptomatic BHP, while maintaining the ease of use they are accustomed to," Urologix said. Shares were up $1 to $4.36.
fell 6% after the stem-cell company said it plans to sell 15.9 million shares of stock at $1.60 apiece, raising about $25.5 million. The price represents a 10% discount to Wednesday's closing price of $1.78. The sale is expected to close during the next few days, the company said. Shares were down 11 cents to $1.67.
( OLGC) fell 5% after the biotech company announced the resignation of its chief executive. OrthoLogic said that James Pusey, who joined the company in March 2005, is leaving to pursue other opportunities. Chairman John Holliman, meanwhile, will assume the title of executive chairman and head the company's business and strategic activities. Randolph Steer has been named president and will head the company's clinical development and regulatory areas. OrthoLogic shares were down 9 cents to $1.87.
rose 2% after the maker of diagnostic products said it plans to sell almost 2.7 million American depository shares to a group of institutional investors for $8.60 apiece, raising $23 million in proceeds. The price represents a 5% discount to Wednesday's closing price of $9.01. Additionally, Trinity said its CEO, Ronan O'Caoimh, agreed to buy about 223,000 shares for $8.95 apiece, or about $2 million in stock, from the company. Trinity plans to use the $25 million in proceeds to fund general corporate purposes. Shares were trading up 22 cents to $9.23.
Other health care volume movers included
, down $1.40 to $34.59;
, down 12 cents to $25.05;
, up 50 cents to $22.19;
St. Jude Medical
, up 87 cents to $37.12;
, up 13 cents to $2.76;
, down 60 cents to $54.70;
, down 72 cents to $5.96;
, up 20 cents to $9.22;
, up $1.02 to $51.60;
, down $1.06 to $71.80;
Johnson & Johnson
, up 27 cents to $58.67;
, up 26 cents to $24.80;
, down 21 cents to $14.21; and
( SGP), down 5 cents to $18.99.